Cardium Therapeutics, Inc. (CXM) Selects AMRI for Market Introduction of Excellagen

Cardium Therapeutics, a San Diego based health sciences and regenerative medicine company, and its subsidiary, Tissue Repair Company, have contracted the Burlington, Massachusetts, site of Albany Molecular Research (AMRI) to manufacture sterile pre-filled syringes, in support of the U.S. introduction of Excellagen, a collagen product for the management of diabetic foot ulcers, pressure ulcers, and other dermal wounds.

Excellagen™, introduced to the U.S. market in March of this year, is an FDA-cleared highly-refined fibrillar collagen-based topical gel (2.6%) designed to support favorable wound care management for the management of diabetic ulcers, partial and full thickness wounds, pressure ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh’s surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, skin tears) and draining wounds.

Cardium Therapeutics is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses having the potential to address significant unmet medical needs with definable pathways to commercialization and monetization. The company’s current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company’s in-house MedPodium Health Sciences healthy lifestyle product platform.

Cardium’s business model is designed to create multiple opportunities for success while avoiding reliance on any single technology platform or product type. The goal is to leverage Cardium’s skills in late-stage product development in order to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization. The company continues to pursue cost-effective acquisitions, and will also consider various corporate development transactions designed to place their product candidates into larger organizations or with select partners.

For additional information, visit www.CardiumTHX.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html